Subscribe to RSS
DOI: 10.1055/s-0031-1296188
Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation
Publication History
Publication Date:
28 November 2011 (online)
![](https://www.thieme-connect.de/media/amf/201103/lookinside/thumbnails/10.1055-s-0031-1296188-1.jpg)
Abstract
The present study was designed to determine the pharmacokinetic profiles of a once-daily formulation of tacrolimus (CAS 104987-11-3; TAC-once) in patients before and after introduction of renal transplantation. Pharmacokinetic parameters for tacrolimus were almost comparable among patients receiving TAC- once before, 2 weeks after and 3 weeks after renal transplantation. Among various parameters, Ctrough correlated most closely with the area under the concentration-time curve during 24 h (AUC0–24) (R2 = 0.82, P < 0.001), while no consistent correlation was observed between AUC0–24 and concentrations at 2 h or 4 h, or the dose of TAC-once. The clinical outcomes such as the incidence of acute rejection, renal tissue injury and cytomegalovirus infection were evaluated during the first 3 weeks and 3 months after transplantation, and the data were compared with the historical data obtained from patients who had received the conventional twice-daily formulation of tacrolimus (TAC-twice). There were no significant differences in the incidence of such clinical outcomes between the two groups. These findings suggest that Ctrough is useful for therapeutic monitoring of tacrolimus in patients receiving TAC-once. In addition, pharmacokinetics and clinical outcomes were comparable between TAC-once and TAC-twice formulations.
-
References
- 1 Japanese FK 506 Study Group. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Transplant Proc. 1991; 23: 3085-8
- 2 Cross SA, Perry CM. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs. 2007; 67: 1931-43
- 3 Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009; 31: 139-52
- 4 Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009; 9: 2505-13
- 5 Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999; 31: 296-8
- 6 Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43: 623-53
- 7 First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit. 2008; 30: 159-66
- 8 Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J et al. Time-related clinical determinants of longterm tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004; 43: 741-62
- 9 Wente MN, Sauer P, Mehrabi A, Weitz J, Büchler MW, Schmidt J et al. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation. Clin Transplant. 2006; 20 (Suppl 17) 80-4
- 10 Mathew BS, Fleming DH, Jeyaseelan V, Chandy SJ, Annapandian VM, Subbanna PK et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2008; 66: 467-72
- 11 Jørgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002; 17: 1487-90
- 12 Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007; 63: 1039-44
- 13 Silva Jr HT, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007; 7: 595-608
- 14 Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extendedrelease formulation in stable kidney transplant recipients. Transplantation. 2007; 83: 1648-51
- 15 Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc. 2009; 41: 2323-5
- 16 Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008; 66: 207-14
- 17 Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-75
- 18 Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant. 2009; 24: 2269-76